Iterum Therapeutics (NASDAQ:ITRM) Stock Rating Reaffirmed by HC Wainwright

Iterum Therapeutics (NASDAQ:ITRM)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Tuesday, Benzinga reports. They currently have a $6.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 277.36% from the stock’s current price.

Iterum Therapeutics Trading Up 3.9 %

Shares of ITRM opened at $1.59 on Tuesday. The stock has a fifty day moving average price of $1.52 and a two-hundred day moving average price of $1.51. The company has a debt-to-equity ratio of 3.63, a quick ratio of 1.89 and a current ratio of 1.89. Iterum Therapeutics has a 52-week low of $0.62 and a 52-week high of $2.50. The company has a market cap of $26.32 million, a price-to-earnings ratio of -0.51 and a beta of 2.36.

Iterum Therapeutics (NASDAQ:ITRM) last released its earnings results on Thursday, March 28th. The company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.08. Analysts predict that Iterum Therapeutics will post -1.75 EPS for the current fiscal year.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.